OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← The British Transplantation Society

2022-10-31-accounts

Charity registration number 1098584

Company registration number 4691176 (England and Wales)

THE BRITISH TRANSPLANTATION SOCIETY

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 OCTOBER 2022

THE BRITISH TRANSPLANTATION SOCIETY

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees N Torpey
L Burnap
C Wilson
K Mennon
Secretary C Wilson
Charity number 1098584
Company number 4691176
Registered office St James House
Vicar Lane
Sheffield
S1 2EX
Auditor Mitchell Charlesworth (Audit) Limited
3rd Floor
5 Temple Square
Temple Street
Liverpool
Merseyside
L2 5RH
Bankers Bank of Scotland plc
West End Office
14-16 Cockspur Street
London
SW1Y 5BL

THE BRITISH TRANSPLANTATION SOCIETY

CONTENTS

Page
Trustees' report 1 - 7
Independent auditor's report 8 - 11
Statement of financial activities 12
Balance sheet 13
Notes to the financial statements 14 - 24

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) FOR THE YEAR ENDED 31 OCTOBER 2022

The trustees present their annual report and financial statements for the year ended 31 October 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Articles of Association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The principal activities of the company are to advance transplantation by:-

By being the voice of transplantation for all solid organs within the UK, the Society aims to benefit the general public and patients by ensuring that up-to-date knowledge and best practice in transplantation is shared widely between all professional groups, that research that advances the understanding of transplantation is supported and encouraged and that the media is engaged to promote the benefits of organ donation and transplantation and to ensure accurate representation of topical news items.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Strategic report

Achievements and performance

Kingston Smith Association Management (KSAM) continued to provide support as the BTS secretariat during 2021/22, but due to restructuring and rebranding changed their name to Moore Insight. On October the 20th the Trustees met with the Secretariat and Richard Jones, Director Moore Insight, to discuss the contract and review the services provided. This has become an ongoing annual review meeting after the new contract was signed in 2021. Events, membership, accounts, and media engagement were examined in turn and a small increase in hours agreed. The more concerning matter from the financial perspective was an inflationary rise in the cost of secretariat services which was eventually settled at 7.5% - in line with the current levels of inflation which at the time of writing are running closer to 10%.

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

The Society had an active year in 2021/22, consolidating activities in line with the strategic plan, originally published in 2015 and reviewed in June 2017. Key priorities are to:

The Society in 2021 had four affiliated organisations: The Herrick Club, Solid Organ Transplant Pharmacists Association, British Liver Transplant Group and the British Urology Transplant Society (which became an affiliated society in 2019).

The Society continues to welcome applications in line with the policy agreed in 2016 and in 2022 we welcomed the British Association of Renal Transplant Anaesthetists (BARTA) as a further affiliate. To consolidate the affiliates and ensure that Council meetings remain manageable, agreement was reached within the executive to maintain the current Council representation and for new affiliates to be assigned representation according to overlapping interest areas. BARTA will therefore be represented on council by the Renal Transplant Surgery Councillor.

The Executive and Council continue to represent the Society’s views to a number of organisations including: the NHS Blood and Transplant advisory and strategy groups and National Organ Donation Committee; The Association of Surgeons of Great Britain and Ireland; The National Institute of Health and Clinical Excellence; The Renal Association; The British Renal Society; the UK Renal Registry; the Renal Transplant Clinical Reference Group for NHS England; the Kidney Health Partnership and other professional organisations. During the past four years, the BTS has been invited to co-host an increasing number of joint sessions at other professional society meetings and Congresses, for example UK Kidney Week (run by the Renal Association and British Renal Society). A policy is now in place to engage in these events, whilst ensuring that there is mutual benefit to all Societies involved.

The redevelopment of the public-facing website in 2016 was welcomed by members and has enhanced the profile of the Society. The website has been crucial over the last years in dissemination of regular updates in relation to SARS-CoV-2. This is maintained and managed by Thumb Design who delivered the redesign. At that time, it was agreed that Moore Insight would retain operational control of the more complex members' area of the website and update it to ensure that it was fit for purpose. This was successfully completed in 2017 and the continuity of these essential membership functions has been maintained throughout. The website provides updates on events of interest, a link to the Executive Committee newsletters and links to minutes of relevant meetings at which the society has representation.

The BTS appointed a Communications Officer for the first time in 2016 on a sessional basis. This provided a useful point of contact to facilitate responses to media and news enquiries in a timely and consistent manner and in developing social media communications and policies for the Society. The Communications officer stood down in 2020 and the new contract with Moore Insight has moved formal communications to within the Secretariat. An area of active development is a Social Media policy to split formal and informal communications. In 2022 a Society Communications group was formed consisting of a Councillor, the General Secretary and Secretrariat representative to oversee all Social Media activity. For now the focus will be the Twitter platform.

The Society continued its on-going work drafting and revising standards and guidelines either alone or in collaboration with other societies for the clinical management of various aspects of transplantation. The Guidelines and Standards produced by the Society are accredited by NICE and have developed a global reputation. A new Chair was appointed in 2021 and a pledge to continue producing guidelines to NICE accredited standards, which entails a commitment to commercial literature searches.

The Society has an active bursary scheme, which supports a maximum of 10 non-consultant members up to £500 each to attend national and international meetings and educational events. The bursary scheme has been reviewed and criteria for applications revised to improve awareness of the scheme and to ensure equitable allocation and representation across all sectors of the Society.

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

Annual General Meeting

The Annual General Meeting (AGM) of the Society took place online on the 1st of March 2022. The results of the 2022 elections to the Council and Sub-Committees were announced. The election was run on-line by Civica Election Services (formerly known as the Electoral Reform Services). 170 of 471 eligible members voted, representing a turnout of 36.1%. There was a general discussion about why the turn-out was so low and the general agreement was that this was due to the postponement of the Conference in view of Covid pressures.

Three council positions were included in the election, and two sub-committee positions. No changes to the Trustees took place at the AGM:

The next AGM will be held on Thursday 3rd March 2023.

Annual Congress

The 25th Annual Congress of the Society was held at the Waterfront Congress Centre, Belfast 5th to 7th September – the conference had been postponed after an EGM in January decided it would be too risky to go ahead in March due to the Covid situation. The statistics are as follows:

This year’s Congress incorporated the celebrations of the Society’s 50th Anniversary and included special events to mark the occasion. A number of Honorary memberships and Lifetime Achievement Awards were conferred.

Honorary Membership

Prof John Dark Dr James Douglas Prof Dorry Segev (USA) Prof Lori West (USA) Prof Elizabeth Pomfret (USA)

Lifetime Achievement Awards

Prof Chris Watson Prof Mike Nicholson Prof Darius Mirza Prof Peter Friend Miss Lisa Burnapp Prof Sir Roy Calne Prof Sir Magdi Yacoub Prof Sir Peter Morris

The Roy Calne Award is made to the best clinical paper published in the academic literature. There were 5 submissions and the award was made to Oliver Tavabie, King’s College, for his publication entitled “A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure”.

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

The Medawar Medal for the best clinical abstract presented was awarded to Hannah Maple from Guy’s and St Thomas’ NHS Foundation Trust, for her paper “Do unspecified (non-directed) kidney donors in the United Kingdom differ from specified donors?: Results from the BOUnD study”. The best basic science paper was awarded to Ashley Priddey, Department of Surgery, University of Cambridge, United Kingdom for his paper “Direct alloantibody affinity profiling in patient sera to improve immunological risk assessment in transplantation”

The next Congress will be held in Edinburgh between March the 1st and 3rd 2023.

COVID-19

The news and NHS agenda remained dominated by the SARS-Cov2 pandemic in 2022. The BTS continued to link with NHSBT and provide co-ordinated up-to-date information relating to the changing situation to transplant units around the United Kingdom.

BTS Andrew Paris Memorial Fellowship

In 2021, the British Transplantation Society was approached by Susan Paris, widow of the late Andrew Paris, who had been instrumental in setting up and running the St John Ambulance Airwing. This service, provided by the well known charity, had been established in 1972 to provide a volunteer air service for the rapid transport of organs, drugs, blood supplies and patients when other means were not available.

Under Andrew Paris’s careful administration, the charitable donations and investments flourished, and fellowships for junior healthcare personnel have been provided on an annual basis to continue the movement of transplant knowledge and experience, in lieu of physical organs. On Andrew’s death, the British Transplantation Society was offered a generous bequest and asked to explore how these funds might be used. Following consultation with the BTS Executive and Council, a working group was established to draft a proposal, which was subsequently presented and ratified at the Annual General Meeting of the Society in March 2022.

Transplant healthcare professionals, and ultimately patients, benefit from the opportunity to travel and learn from best practice, establish new techniques and pass on lessons learned to their colleagues. This practice has been established and ingrained within the Society by the original St John Airwing Travelling Bursary. We will offer a single travelling fellowship up to a maximum value of £7.5k per annum to a member of the society who wishes to travel, for a short period of time, to another unit within the United Kingdom or abroad for a specific purpose. There will be an open competition administered by the BTS Education committee and General Secretary and overseen by the BTS Executive.

The Education committee, with support from the General Secretary, will distribute and promote the Fellowship, collate the application forms and provide a shortlist for the Award committee to score and award. The Award committee will be chaired by the Society President and include the BTS Executive and the chair of the Education committee.

How the Charity operates for the public benefit

By being the voice of transplantation for all solid organs within the UK, the Society aims to benefit the general public and patients by ensuring that:

  1. Up-to-date knowledge and best practice in transplantation are shared widely between all professional groups and throughout the wider transplant community.

  2. Research that advances the understanding of transplantation is supported and encouraged.

  3. The media is engaged to promote the benefits of organ donation and transplantation and to ensure accurate representation of topical news items.

Financial review

The results for the year and the charity’s financial position at the end of the year are shown in the attached accounts.

The statement of financial activities shows a net deficit for the year of £4,536 (2021: surplus £22,476) and total reserves now stand at £280,038 (2021: £284,574).

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

Reserves policy

The Council reviews its reserves policy on a yearly basis.

The Council has established that the target level of general funds (being unrestricted and undesignated) in the Society is £120,000. These are required to: -

The current level of general funds remains above the reserve.

The reserves policy will continue to be monitored by the trustees.

Investment Powers and Policy

Under the Memorandum and Articles of Association, the charity has the power to invest in any lawful way the trustees wish.

Risk review

The trustees continually assess the major risks to which the Society is exposed, particularly those related to the operations and finances of the organisation and are satisfied that systems are in place to mitigate the Society’s exposure to the major risks.

The trustees regard the major risks to be the loss of one or more corporate sponsors, and having to cancel the Annual Congress requiring reimbursement of the income generated resulting in a deficit from costs that will have been incurred and which would not be recoverable.

Plans for future periods

The Society will continue to be the voice of solid organ transplantation in the United Kingdom and aim to deliver and review its Strategic aims to reflect the views and requirements of the membership. It has committed to exploring the options for increasing patient and public engagement in its future activities.

Structure, governance and management

The charity is constituted as a company limited by guarantee and governed by its Memorandum and Articles of Association. There is no share capital and every member of the company undertakes to contribute to the assets of the company while he/ she is a member or within one year after he/she ceases to be a member, such amounts as may be required, not exceeding £1.00 in the event of winding up. The company is registered under the Charities Act 2011 (No. 1098584) and as such is not liable to income tax, corporation tax and capital gains tax.

Trustees

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

N Torpey L Burnap C Wilson K Mennon

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

Appointment of trustees

The trustees of the Society are appointed at general meetings, each individual appointment being for a term of office not exceeding the number of successive years as specified in the Rules.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

Organisation

The business of the Society is managed by the Trustees, who may exercise all the powers of the Society. The Trustees of the Society shall be the President, Vice President, Treasurer and General Secretary.

The Council consists of the four Trustees together with elected councillors and other persons co-opted to Council for specific tasks or in support of the work of the Council. The Council has responsibility for the strategic direction of the Society and is the forum for discussion regarding specific issues, which may affect the Society or its members. The Council also has responsibility regarding the planning and management of the annual meeting of the Society. Some of the organisation of this meeting is delegated to the Congress Organising Committee but final decisions rest with the trustees.

The Society has established Committees to manage specified aspects of the Society’s activities. There is a minimum of Ethics, Education, Clinical Trials and Research and Standards Committees. Each Committee has a chairperson who is either co-opted by Council or elected by the members for a period of three years. The responsibilities of the Committees and the Committee chairpersons are set out in the rules of the Society. No Committee shall act independently of the Council and final authority, including overall financial matters of the Society, rests with the trustees.

Trustee induction and training

A standard induction procedure and training is provided to all new trustees taking up office.

Statement of trustees' responsibilities

The trustees, who are also the directors of The British Transplantation Society for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

THE BRITISH TRANSPLANTATION SOCIETY

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

Auditor

Following the transfer of the business of Mitchell Charlesworth LLP to Mitchell Charlesworth (Audit) Limited on 15 June 2022, and having expressed a willingness to continue in office, a resolution for the appointment of Mitchell Charlesworth (Audit) Limited will be proposed at the forthcoming Annual General Meeting.

Disclosure of information to auditor

Each of the trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The trustees' report, including the strategic report, was approved by the Board of Trustees.

C Wilson

Trustee

1 March 2023

THE BRITISH TRANSPLANTATION SOCIETY

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF THE BRITISH TRANSPLANTATION SOCIETY

Opinion

We have audited the financial statements of The British Transplantation Society (the ‘charity’) for the year ended 31 October 2022 which comprise the statement of financial activities, the balance sheet and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

THE BRITISH TRANSPLANTATION SOCIETY

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS OF THE BRITISH TRANSPLANTATION SOCIETY

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

THE BRITISH TRANSPLANTATION SOCIETY

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS OF THE BRITISH TRANSPLANTATION SOCIETY

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:

(i) The presentation of the charity's Statement of Financial Activities, (ii) the charity's accounting policy for revenue recognition (iii) the overstatement of Congress and other costs. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and the Statement of Recommended Practice - 'Accounting and Reporting by Charities' issued by the joint SORP making body .

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the charity’s ability to operate or to avoid a material penalty. These included Data Protection Regulations.

THE BRITISH TRANSPLANTATION SOCIETY

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS OF THE BRITISH TRANSPLANTATION SOCIETY

Audit response to risks identified

As a result of performing the above, we identified the presentation of the charity's Statement of Financial Activities, revenue recognition and overstatement of Congress and other costs as the key audit matters related to the potential risk of fraud. The key audit matters section of our report explains the matters in more detail and also describes the specific procedures we performed in response to those key audit matters.

In addition to the above, our procedures to respond to risks identified included the following:

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Philip Griffiths (Senior Statutory Auditor) for and on behalf of Mitchell Charlesworth (Audit) Limited 1 March 2023

Accountants Statutory Auditor

3rd Floor 5 Temple Square Temple Street Liverpool Merseyside L2 5RH

THE BRITISH TRANSPLANTATION SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 OCTOBER 2022

Unrestricted
Restricted
funds
funds
2022
2022
Notes
£
£
Income from:
Donations and legacies
2
10,021
10,000
Charitable activities
3
366,940
-
Investments
4
280
-
Total income
377,241
10,000
Expenditure on:
Charitable activities
5
378,363
13,414
Net (expenditure)/income for the
year/
Net movement in funds
(1,122)
(3,414)
Fund balances at 1 November
2021
228,078
56,496
Fund balances at 31 October
2022
226,956
53,082		 Total
Unrestricted
Restricted
funds
funds
2022
2021
2021
£
£
£
20,021
131
-
366,940
223,648
-
280
162
-
387,241
223,941
-
391,777
200,887
579
(4,536)
23,054
(579)
284,574
205,024
57,075
280,038
228,078
56,496		 Total
2021
£
131
223,648
162
223,941
201,466
22,475
262,099
284,574

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

THE BRITISH TRANSPLANTATION SOCIETY

BALANCE SHEET

AS AT 31 OCTOBER 2022

2022
Notes
£
Current assets
Stocks
14
1,264
Debtors
15
146,710
Cash at bank and in hand
255,941
403,915
Creditors: amounts falling due within one
year
16
(123,877)
Net current assets
Income funds
Restricted funds
18
Unrestricted funds		 £
280,038
53,082
226,956
280,038		 2021
£
-
85,975
281,034
367,009
(82,435)		 £
284,574
56,496
228,078
284,574

The financial statements were approved by the Trustees on 1 March 2023

N Torpey Trustee

Company registration number 4691176

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 OCTOBER 2022

1 Accounting policies

Charity information

The British Transplantation Society is a private company limited by guarantee incorporated in England and Wales. The registered office is St James House, Vicar Lane, Sheffield, S1 2EX. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The nature of the charity's operations and principal activities are described in the Trustees' Report on page 1 of these financial statements.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Income from charitable activities incorporating membership fees is deferred until entitlement to the income has passed when received in advance.

No amount is included in the financial statements for volunteer time in line with the SORP (FRS 102).

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

1 Accounting policies

(Continued)

Investment income is earned through holding assets for investment purposes such as bank deposits and largely comprises interest. Interest income is recognised using the effective interest method.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a pro-rata basis consistent with the use of the resources.

Website

33% per annum

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Equipment

20% per annum

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

1 Accounting policies

(Continued)

1.7 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through income and expenditure, are assessed for indicators of impairment at each reporting date. Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected.

If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in net income/(expenditure) for the year.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in net income/(expenditure) for the year.

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

1 Accounting policies

(Continued)

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the charity transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.

1.10 Taxation

The charity is an exempt charity within the meaning of Schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1, Schedule 6 of the Finance Act 2010 and therefore meets the definition of a charitable company for UK corporation tax purposes.

2 Donations and legacies

Unrestricted Restricted Total Unrestricted
funds funds funds
2022 2022 2022 2021
£ £ £ £
Donations and gifts 10,021 10,000 20,021 131

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

3 Charitable activities

Subscriptions &
memberships
Congress &
meetings
2022
2022
£
£
Corporate subscriptions
58,750
-
Individual memberships
59,630
-
Annual Congress income
-
222,196
Other meetings income
-
13,575
Other income
-
12,789
118,380
248,560		 Total
2022
Subscriptions &
memberships
Congress &
meetings
2021
2021
£
£
£
58,750
51,250
-
59,630
52,025
-
222,196
-
118,208
13,575
-
2,165
12,789
-
-
366,940
103,275
120,373		 Total
2021
£
51,250
52,025
118,208
2,165
-
223,648

4 Investments

Interest receivable

Unrestricted Unrestricted
funds funds
2022 2021
£ £
280 162

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

5 Charitable activities

Annual Congress
Other meetings
Other expenditure
Corporate partners
Grant funding of activities
(see note 6)
Share of support costs (see
note 7)
Share of governance costs
(see note 7)
Analysis by fund
Unrestricted funds
Restricted funds		 Grants
payable
Congress &
other
meetings
2022
2022
£
£
-
254,923
-
23,889
-
9,923
-
3,113
-
291,848
4,914
-
-
80,949
-
14,066
4,915
386,862
1,501
376,862
3,414
10,000
4,915
386,862		 Total
2022
£
254,923
23,889
9,923
3,113
291,848
4,914
80,949
14,066
391,777
378,363
13,414
391,777		 Grants
payable
Congress &
other
meetings
2021
2021
£
£
-
102,151
-
5,248
-
-
-
-
-
107,399
2,178
-
-
80,145
-
11,743
2,178
199,287
1,599
199,287
579
-
2,178
199,287		 Total
2021
£
102,151
5,248
-
-
107,399
2,178
80,145
11,743
201,465
200,886
579
201,465

6 Grants payable

Grants payable Grants payable
2022 2021
£ £
Grants for
BTS Bursary 3,414 579
Medawar Medal 1,500 1,600
4,914 2,178

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

7
Support costs
Support costs
Governance
costs
2022 Support costs
Governance
costs
£
£
£
£
£
IT and software
16,008
-
16,008
9,526
-
Printing, postage and
stationery
142
-
142
1,348
-
Legal and professional
300
-
300
400
-
Secretariat
58,652
-
58,652
64,539
-
Bank charges
3,483
-
3,483
2,285
-
Irrecoverable VAT
943
-
943
2,047
-
Telephone
600
-
600
-
-
Miscellaneous expenses
821
-
821
-
-
Audit fees
-
6,309
6,309
-
6,125
Trustee expenses
-
893
893
-
-
Meeting and AGM
expenses
-
6,864
6,864
-
5,618
80,949
14,066
95,015
80,145
11,743
Analysed between
Charitable activities
80,949
14,066
95,015
80,145
11,743
8
Net movement in funds
2022
£
Net movement in funds is stated after charging/(crediting)
Fees payable to the company's auditor for the audit of the company's financial
statements
6,309		 2021
£
9,526
1,348
400
64,539
2,285
2,047
-
-
6,125
-
5,618
91,888
91,888
2021
£
6,125

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year. Expenses totalling £1,388 were reimbursed to three trustees during the year (2021 £Nil).

Goods were sold to one trustee during the year for £108 (2021 £Nil).

10 Employees

There were no employees during the year.

11 Taxation

The company is a registered charity and no provision for taxation is considered necessary.

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

12 Intangible fixed assets
Website
£
Cost
At 1 November 2021 and 31 October 2022 28,250
Amortisation and impairment
At 1 November 2021 and 31 October 2022 28,250
Carrying amount
At 31 October 2022 -
At 31 October 2021 -
13 Tangible fixed assets
Equipment
£
Cost
At 1 November 2021 4,422
At 31 October 2022 4,422
Depreciation and impairment
At 1 November 2021 4,422
At 31 October 2022 4,422
Carrying amount
At 31 October 2022 -
At 31 October 2021 -
14 Stocks
2022 2021
£ £
Finished goods and goods for resale 1,264 -

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

15
Debtors
Amounts falling due within one year:
Trade debtors
Other debtors
Prepayments and accrued income
No bad debts were provided for during the year (2021 £Nil).		 2022
£
15,430
29,398
101,882
146,710		 2021
£
15,250
9,230
61,495
85,975

16 Creditors: amounts falling due within one year

Notes
Deferred income
17
Trade creditors
Accruals
Deferred income
Other deferred income		 2022
£
91,009
20,640
12,228
123,877
2022
£
91,009		 2021
£
49,558
26,677
6,200
82,435
2021
£
49,558

17 Deferred income

Deferred income comprises membership deferrals and income relating to the 2023 Annual Congress and other meetings.

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2022

18 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Balance at
1 November
2020
£
Clinical Trials Fund
19,521
Hoffenberg Memorial Lecture
Fund
23,274
BTS Bursary Scheme
14,280
Warren's Wish Fund
-
57,075		 Movement in funds
Resources
expended
Balance at
1 November
2021
Incoming
resources
Resources
expended
Balance at
31 October
2022
£
£
£
£
£
-
19,521
-
-
19,521
-
23,274
-
-
23,274
(579)
13,701
-
(3,414)
10,287
-
-
10,000
(10,000)
-
(579)
56,496
10,000
(13,414)
53,082		 Movement in funds
Resources
expended
Balance at
1 November
2021
Incoming
resources
Resources
expended
Balance at
31 October
2022
£
£
£
£
£
-
19,521
-
-
19,521
-
23,274
-
-
23,274
(579)
13,701
-
(3,414)
10,287
-
-
10,000
(10,000)
-
(579)
56,496
10,000
(13,414)
53,082
53,082

The Clinical Trials Fund represents income from the National Kidney Research Fund which is available for use by the Clinical Trials sub-committee.

The Hoffenberg Memorial Lecture Fund represents a donation to fund an annual lecture on transplantation in honour of the memory of Sir Raymond Hoffenberg.

The BTS Bursary Scheme balance represents monies previously provided by the pharmaceutical companies, Astellas and Novartis, for a bursary scheme to allow members to attend the American Transplantation Congress and the European Society for Organ Transplantation Congress. The schemes have not been renewed but the companies concerned have allowed the Society to retain the balance of monies to fund future bursaries for attendance at BTS's own meetings.

The Warren's Wish Fund represents a charitable donation to fund the dissemination of guidance regarding lung transplants.

19 Analysis of net assets between funds

Unrestricted
funds
Restricted
funds
2022
2022
£
£
Fund balances at 31
October 2022 are
represented by:
Current assets/(liabilities)
226,956
53,082
226,956
53,082		 Total
Unrestricted
funds
Restricted
funds
2022
2021
2021
£
£
£
280,038
228,078
56,496
280,038
228,078
56,496		 Total
2021
£
284,574
284,574

20 Capital commitments

There were no capital commitments at 31st October 2022 (2021 - £Nil).

THE BRITISH TRANSPLANTATION SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2022

21 Related party transactions

There were no disclosable related party transactions during the year (2021 - none).

In the opinion of the trustees there is no ultimate controlling party.

THE BRITISH TRANSPLANTATION SOCIETY - SUMMARY ACCOUNTS

Statement of Financial Activities for the year ended 31st October 2022

Balance Sheet at 31st October 2022

2022 2021 2022 2021
Unrestricted Restricted Total Total Fixed assets
Income from: Intangible assets - -
Corporate subscriptions 58,750 - 58,750 51,250 Tangible assets - -
Individual memberships 59,630 - 59,630 52,025
Meetings income 235,771 - 235,771 120,373 - -
Other income 12,789 - 12,789 -
Bank interest 280 - 280 162 Current assets
Donations and grants 10,021 10,000 20,021 131 Stock 1,264 -
Debtors 146,710 85,975
Total Income 377,241 10,000 387,241 223,941 Cash at bank 255,941 281,034
Expenditure on: 403,915 367,009
Charitable activities 378,363 13,414 391,777 201,466 Creditors
Amounts falling due within one year (123,877) (82,435)
Total expenditure 378,363 13,414 391,777 201,466
Net current assets 280,038 284,574
Net income/(expenditure) for the year (1,122) (1,122)
(3,414)		 (4,536) 22,475
Net assets £280,038 £284,574
Net movement in funds (1,122) (1,122)
(3,414)		 (4,536) 22,475 Funds
Accumulated funds brought forward 228,078 56,496 284,574 262,099
Unrestricted funds
Accumulated funds carried forward £226,956 £53,082 £280,038 £284,574 General funds 226,956 228,078
Restricted funds
Independent Auditor’s Statement on Summary Accounts to the Members of The British Transplantation Society Independent Auditor’s Statement on Summary Accounts to the Members of The British Transplantation Society Clinical Trials Fund 19,521 19,521
We have examined the summary financial information for the year ended 31st October 2022 set out above. Hoffenberg Memorial Lecture Fund 23,274 23,274
BTS Bursary Scheme 10,287
 13,701
Respective responsibilities of the directors and auditors
The trustees are responsible for preparing the summary financial information in accordance with applicable United The trustees are responsible for preparing the summary financial information in accordance with applicable United The trustees are responsible for preparing the summary financial information in accordance with applicable United £280,038 £284,574

The trustees are responsible for preparing the summary financial information in accordance with applicable United Kingdom law.

Trustees’ Statement

Our responsibility is to report to you our opinion on the consistency of the summary financial information with the full annual accounts and the Trustees’ Report.

We also read the other information contained in the summary accounts and consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the summary financial information.

Our report on the company’s full annual accounts describes the basis of our opinion on those accounts and on the Trustees’ Report.

The auditor has issued unqualified reports on the full annual accounts and on the consistency of the Trustees’ Report with those accounts. Their report on the full annual accounts contained no statement under Sections 498(2)(a) or (b) or 498(3) of the Companies Act 2006.

For further information, the full accounts, the auditors’ report on those accounts and the Trustees’ Report should be consulted. Copies can be obtained from BTS Secretariat, Ground Floor, 4 Victoria Square, St Albans, Hertfordshire AL1 3TF.

The annual accounts were approved by the Board of Trustees on 1 March 2023.

Basis of opinion

We have carried out the procedures which we considered necessary to ascertain whether the summarised accounts are consistent with the full accounts from which they have been prepared.

.

Opinion

In our opinion, the summary accounts above are consistent with the full accounts for the year ended 31st October 2022.

DR. N. TORPEY Trustee

MITCHELL CHARLESWORTH (AUDIT) LIMITED Accountants & Statutory Auditor 5 Temple Square Temple Street Liverpool L2 5RH 1 March 2023

REPORT TO THE TRUSTEES ON THE MATTERS ARISING FROM THE AUDIT OF:

THE BRITISH TRANSPLANTATION SOCIETY FOR THE YEAR ENDED 31 OCTOBER 2022

The British Transplantation Society Audit Summary Memorandum Year ended 31 October 2022

Introduction

In accordance with International Standards on Auditing (UK), we are pleased to present our Audit Summary Memorandum arising from the audit of the accounts of The British Transplantation Society for the year ended 31 October 2022.

mitchell 0)

A schedule of misstatements that have not been adjusted following discussions with Pavlina Filakova is included in this document at Appendix 2. You have confirmed that having regard to the size and qualitative nature of these misstatements that they should not be adjusted.

Significant deficiencies in the accounting and internal control systems

The purpose of this report is to provide an overview of the entity’s results and activities for the year, highlighting any key audit and accounting issues which have come to our attention during the audit. It is also prepared to assist the trustees in their consideration of the accounts and to share our recommendations for areas of improvement. It also covers any future issues for the trustees’ consideration.

Scope of work

The accounts were reviewed to ensure they have been prepared in accordance with the requirements of the Companies Act 2006 and United Kingdom Generally Accepted Accounting Practice being the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Statement of Recommended Practice (SORP 2019) ‘Accounting and Reporting by Charities (FRS 102)’.

As you are aware from our letter of engagement, our audit procedures are designed towards testing the accounting and internal control systems in operation upon which we have based our assessment of the risk of material misstatement within the accounts.

There are no matters which we feel need to be brought to the attention of the trustees.

An update on matters brought to your attention in the previous year is included at Appendix 3.

Disclaimer

This report includes information which has been provided by, or is based upon discussions with management and staff, in addition to the independent findings of our work.

Conclusion

We are pleased to report that subject to the discussion of the matters raised in this report, and the completion of our post balance sheet events review, it is our intention to issue an unqualified report on the accounts.

Adjustments to the accounts

These matters came to light during the course of our normal audit tests which are designed to assist us in forming our opinion on the accounts. Our tests may not necessarily highlight all the weaknesses in internal control and accounting practices that a specific investigation might uncover and should not be relied upon to do so. However, if any irregularity did come to our attention during our audit tests, we would, of course, inform you immediately.

The points are raised for the sole use of the trustees of The British Transplantation Society and must not be shown to third parties without our prior consent. No responsibility is accepted by Mitchell Charlesworth (Audit) Limited towards any party acting or refraining from action as a result of these points.

A schedule of the adjustments that have been agreed with Pavlina Filakova is included at Appendix 1 to this report.

Misstatements not adjusted

Letter of Representation

1 | P a g e

The British Transplantation Society Audit Summary Memorandum Year ended 31 October 2022

==> picture [102 x 40] intentionally omitted <==

----- Start of picture text -----
mitchell )
----- End of picture text -----

During the course of our audit, various representations were verbally made to us by the Secretariat and the trustees, and we ask you for written confirmation of these in a letter of representation.

If you have any queries, please contact Philip Griffiths or Stephen Easterby in the first instance.

Mitchell Charlesworth (Audit) Limited

Qualitative aspects of the entity’s accounting and financial reporting practice

Independence

Our audit was performed in accordance with International Standards on Auditing (UK) and the Ethical Standard.

In accordance with those requirements, we are required to consider any threats to our independence arising from the provision of non-audit services and a long association.

3rd Floor 5 Temple Square Temple Street Liverpool L2 5RH

24 February 2023

In our opinion, there are adequate safeguards in place that deal with any potential threats to our independence in the conduct of the audit. There are no changes in circumstances that have come to light since the issue of our Audit Planning Strategy.

Other matters

There are no other matters arising from the audit that require reporting to you.

We take this opportunity of expressing our thanks to the staff of Kingston Smith Association Management Limited for their assistance during the course of our work.

Please note that this report has been prepared for the sole use of The British Transplantation Society. It must not be disclosed to third parties, quoted or referred to wholly or in part without our prior written consent. No responsibility is assumed by us to any other person.

2 | P a g e

mitchell 0)

The British Transplantation Society Audit Summary Memorandum Year ended 31 October 2022

Appendix 1: Schedule of adjustments

Impact on
Debit Credit surplus/(deficit)
Surplus per first draft accounts (5,538)
1. Stock 1,264 1,264
Other expenses 1,264
Being closing stock
2. Trade debtors 3,841 -
Trade creditors 3,841
Being reallocation of sales ledger credit balances
3. Meeting expenses 139
Annual Congress expenditure 123
Accruals 262 (262)
Being additional accruals
Adjusted surplus per final accounts (4,536)

3 | P a g e

mitchell 0)

The British Transplantation Society

Audit Summary Memorandum Year ended 31 October 2022

Appendix 2: Schedule of unadjusted misstatements

Impact on
Debit Credit surplus/(deficit)
1. Trade debtors 2,565 2,565
Bad and doubtful debts 2,565
Being overstatement of bad debt provision
2. Trade debtors 1,500 1,500
Corporate subscription income 1,500
Being understatement of corporate subscription income
Total impact on surplus/(deficit) 4,065

Total impact on surplus/(deficit)

4 | P a g e

mitchell 4)

The British Transplantation Society Audit Summary Memorandum Year ended 31 October 2022

Appendix 3: Update on significant deficiencies in accounting and internal control systems identified in previous year

Matters arising

Potential risks

Recommendation

Updated position

VAT partial exemption

It was noted that an annual adjustment An annual adjustment must be performed We recommend that a VAT partial is not performed as part of the VAT in accordance with HMRC VAT guidance. If exemption annual adjustment is partial exemption calculations. This the adjustment is not performed, the performed every year. adjustment is necessary to iron out input VAT claimed for a twelve-month fluctuations in the proportion of period will be incorrect. exempt income to standard rated income each quarter for the entire twelve-month period and to adjust the disallowable input VAT for the year accordingly.

An annual adjustment was processed during the current year. This issue has now been addressed.

5 | P a g e